CORD: Webinar 2: When Innovation Rewrites the Pathway
From Canadian Experience to Phase 2 Readiness How can Phase 2 RDDS help Canada anticipate the pathway consequences of new rare and precision therapies - so that screening, diagnosis, eligibility, expertise, delivery, patient choice, monitoring and learning do not have to be rebuilt after each access decision?
